Insight Series

October 17, 2023 | 11:00 AM CT

A key factor to successful gene therapy is efforts to monitor the fate of gene-corrected cells. Lentivirus and AAV vectors can efficiently introduce new genetic material into human cells; however, risks exist for genotoxicity and malignant transformation. This panel of experts will discuss state-of-the-art technologies and assays for integration site profiling, clonality, and oncogenesis.

Speakers

• Moderators: Jessica Lynch, PhD - Johnson and Johnson, and Andrew Wilber, PhD - Southern Illinois University School of Medicine

• Frederic Bushman, PhD - Perelman School of Medicine at the University of Pennsylvania
  Genomic analysis of retroviral and AAV gene therapy vectors and consequences for the human genome

• Markus Grompe, MD - Oregon Health and Science University
  Preclinical evaluation of AAV for safety and efficacy in treatment of metabolic disorders

• Silvana Libertini, PhD - Novartis
  Safety of cell therapy products - methods to assess tumorigenicity

Watch on demand

More ASGCT Insights

Register for more sessions during ASGCT Insights Week, Oct. 16-20. Members and registrants can watch on demand!

• Oct. 16: Best of ASGCT: Annual Meetings Recent Top Abstracts Revisited

• Oct. 18: Risk Assessment for Gene Editing Technologies and Outcomes

• Oct. 19: Treating Genetic Diseases Prior to Birth from Stem Cells to Gene Delivery

• Oct. 20: Friend or Foe? Interplay Between Innate Immune Responses and Non-viral Gene Delivery